An observational study in Mild Cognitive Impairment, Mild Dementia and Dementia Alzheimers, sponsored by Stanford University. Completed at 1 site in United States. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Stanford University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Cognitive Dysfunction by Stanford University — 3 open to participants now, 7 under way, none of them phase 3. Cognitive Dysfunction · Stanford University.
Among the 14 studies in Cognitive Dysfunction by Stanford University, this one is one of 5 that started in 2024, is one of 8 observational ones, and was the 13th registered.
3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.
Browse Cognitive Dysfunction studies →3 of the 14 studies in Cognitive Dysfunction by Stanford University are open now, in 1 country. Recruiting first, the newest first:
Stanford University · Sites in United States
Ages 6–12 · Healthy volunteers
Stanford University · Sites in United States
Ages 65–99 · Healthy volunteers
Stanford University · Sites in United States
Ages 55+
By country, each count listing its studies:
Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.
This study: 65 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 5 started in 2024.
This study's enrollment of 22 is below the median of 150 across 1,000 observational studies indexed under Cognitive Dysfunction.
Median enrollment 135 across the 6 interventional studies, 85 across the 8 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Stanford University is the lead sponsor of 2,171 studies on the registry; 425 are open to participants now.
Of its 268 completed or terminated interventional studies of FDA-regulated products, 207 (77%) have results posted.
2 of the studies in Cognitive Dysfunction by Stanford University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05201534Stanford UniversityInterventions in Mathematics and Cognitive Skills | 2027-08-31 |
| NCT06489847Stanford UniversityAn Objective Assessment Tool for Evaluating Functioning in Older Adults | 2027-10-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies in Cognitive Dysfunction by Stanford University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Neuropsychiatric symptoms (NPS) refer to a range of mental and emotional issues that can be observed through how patients move, perform daily tasks, and express feelings on their faces. In this study, the investigators want to find ways to accurately and unobtrusively track these symptoms in people's homes over time. Our goals are to note when these symptoms happen, predict potential problems, and gather clear data to help doctors make accurate diagnoses.
To do this, the investigators will first collect information from participants who have in-home sensors. the investigators will then use special computer programs that can recognize everyday activities and identify features that connect to scores from the Mild Behavioral Impairment Checklist (MBI-C). These scores will be compared to a questionnaire (NPIQ) filled out by caregivers or family members, along with any relevant information from doctors about the patients' symptoms. The investigators aim to see how these features can help differentiate between types of NPS, such as mood changes and agitation.
Finally, the investigators will create a dashboard for doctors that summarizes the patterns of these symptoms in patients, making it easier to monitor and manage their mental health.
What the investigators would need from participants:
Older Adults - 65+
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
develop a personalized and clinically interpretable NPS assessment system
Assessing NPS relies primarily on clinician observation \& interviews with caregivers, usually within brief \& infrequent clinical visits. Precise assessment and monitoring methods would incorporate objective, patient- \& caregiver-friendly, real-time tools and provide reliable \& frequently captured data. We aim to create a system that can monitoring individual and subsyndromes of NPS; and detect early changes in NPS by automatically quantifying \& detecting relevant behavioral abnormalities based on both intra- \& inter-individual comparisons. Our approach is a video sensor, information processing, \& alert system that utilizes in-home cameras \& ambient sensors with video features that can recognize \& track behaviors securely, pre-defines domains involved in a behavior; personalizes the results by assessing the individual's behavioral norms and the home environment; and analyzes, learns, and provides explainable items from different modalities of data: time, location, video, and audio.
Time frame: 2 year
NPS Clinical Dashboard
Overall, the investigators envision the clinical dashboard as a transformative tool that delivers clear and comprehensive data on each individual. Therefore enhancing the quality of diagnosis of NPS for individuals, leading to better patient interventions and more effective long term management strategies.
Time frame: 1 year
generate Data and support for a large-scale study or clinical trial within the context of an R01.
the ultimate goal of this project is to generate feasibility data and infrastructure for a large-scale study with a possible clinical trial within the context of an R01. In parallel, to translate the technology into clinical practice, we will work with the Stanford Office of Technology Licensing (OTL) to productize the outcomes.
Time frame: 2 years
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2024 to primary completion in Oct 2025, 12 months.
Of 506 non-industry observational studies under Cognitive Dysfunction, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 118. This study's 12 months is below that.
Counting every sponsor, half of 545 studies reached it within 48 months; a quarter within 21 and three quarters within 118.
Completion moved once since we started tracking on Sep 25, 2026: Dec 2026 → Dec 2025, on Nov 16, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.